Carli M, Perilongo G, di Montezemolo L C, De Bernardi B, Ceci A, Paolucci G, Pianca C, Calculli G, Di Tullio M T, Grotto P
Cancer Treat Rep. 1987 May;71(5):525-7.
A phase II multicenter evaluation of cisplatin (90 mg/m2, Day 1) and etoposide (150 mg/m2, Days 2, 3, and 4) in 4-week cycles was carried out in 21 relapsed children with rhabdomyosarcoma (RMS) and six with non-RMS soft tissue sarcomas (NRSTS). Clinical responses were evaluated after four cycles. There were three complete responses (CRs) and four partial responses (PRs) among the 21 patients with RMS and no responses among the patients with NRSTS. The durations of the three CRs and the four PRs were 11, 9, and 8 months, and 5, 2, 2, and 1 month, respectively. Bone marrow and renal toxicity was cumulative and predictable, but not life threatening. The response rate (CR + PR = 33.3%) to cisplatin and etoposide warrants testing as front-line therapy for RMS.
对21例复发性横纹肌肉瘤（RMS）患儿和6例非RMS软组织肉瘤（NRSTS）患者进行了一项II期多中心评估，采用顺铂（90 mg/m²，第1天）和依托泊苷（150 mg/m²，第2、3和4天），每4周为一个周期。四个周期后评估临床反应。21例RMS患者中有3例完全缓解（CR）和4例部分缓解（PR），NRSTS患者无缓解。3例CR和4例PR的持续时间分别为11、9和8个月以及5、2、2和1个月。骨髓和肾脏毒性具有累积性且可预测，但不危及生命。顺铂和依托泊苷的缓解率（CR + PR = 33.3%）值得作为RMS的一线治疗进行测试。
